First National Bank & Trust Co. of Newtown Sells 6,360 Shares of Pfizer Inc. (NYSE:PFE)

First National Bank & Trust Co. of Newtown trimmed its position in Pfizer Inc. (NYSE:PFE) by 10.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,861 shares of the biopharmaceutical company’s stock after selling 6,360 shares during the quarter. First National Bank & Trust Co. of Newtown’s holdings in Pfizer were worth $1,608,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Worth Asset Management LLC acquired a new stake in Pfizer in the first quarter worth about $29,000. Briaud Financial Planning Inc acquired a new position in shares of Pfizer during the 3rd quarter worth about $30,000. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer during the 3rd quarter worth about $34,000. Finally, VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on PFE. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Stock Up 1.8 %

NYSE PFE traded up $0.45 during trading on Friday, hitting $25.84. The stock had a trading volume of 15,257,789 shares, compared to its average volume of 42,113,340. The company has a market capitalization of $146.32 billion, a PE ratio of 71.17, a P/E/G ratio of 1.15 and a beta of 0.61. The company’s 50-day moving average price is $27.14 and its two-hundred day moving average price is $28.74. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the business posted $1.14 EPS. The business’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.